IP Library › Granted Patent US 12,146,138
Granted Patent B2
US 12,146,138 · App. 17/675,800 · Granted Nov 19, 2024

Treatment and diagnosis of inflammatory disorders

Inventors: Zhenglun Zhu (Newton, MA); Hong Gao (Downingtown, PA)
C12N15/1137A61K31/7115A61K35/17C12N5/0645C12N15/113C12Q1/68C12Q1/6883G01N33/5023G01N33/6875A61P29/00C12N2310/11C12N2310/14C12N2310/3233C12Q2600/158G01N2333/4703G01N2800/52G01N2800/7095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,146,138
App. No.
17/675,800
Granted
Nov 19, 2024
Kind
B2
Abstract

A method of treating an inflammatory disorder in a subject, comprising administering to a subject in need thereof a nucleic acid molecule for inhibiting the expression of Hom-1.

Claims (7)

1. A method of treating an inflammatory disorder in a subject in need thereof, wherein an inflamed tissue sample obtained from the subject expresses a higher level of Hom-1 as compared to a normal tissue sample, comprising administering to the subject a morpholino oligonucleotide for inhibiting the expression of Hom-1, wherein the morpholino oligonucleotide is administered naked.

2. The method of claim 1 , wherein the morpholino oligonucleotide has the sequence of SEQ ID NO: 3, 4, 5, or 6.

3. The method of claim 1 , wherein the nucleic acid molecule is administered topically, orally, rectally, nasally, intravenously, intraarticularly, conjunctively, intracranially, intraperitoneally, intrapleurally, intramuscularly, intrathecally, or subcutaneously.

4. The method of claim 1 , further comprising, prior to the administering step, detecting a higher expression level of Hom-1 in an inflamed tissue sample obtained from the subject as compared to a control level.

5. The method of claim 4 , further comprising, after the administering step, detecting the expression level of Hom-1 or an inflammatory cytokine in an inflamed tissue sample obtained from the subject.

6. The method of claim 4 , wherein the control level corresponds to the expression level of Hom-1 in a non-inflamed tissue sample.

7. The method of claim 1 , wherein macrophages in the inflamed tissue sample obtained from the subject expresses a higher level of Hom-1 as compared to a macrophages in a normal tissue sample.

Continuity (3)
Division 16075479
Provisional Application 62291271 · Feb 4, 2016
Related Publication 20220177892A1 · Jun 9, 2022